Maria Luigia Randi: Influence Statistics

Maria Luigia Randi

Maria Luigia Randi

First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy | Department of Medicine-DIMED, University of Padua, Via Giustiniani 2, 35128, Padua, Italy ...

Maria Luigia Randi: Expert Impact

Concepts for which Maria Luigia Randi has direct influence: Essential thrombocythemia , Polycythemia vera , Pregnancy complications , Large cohort , Acute leukemia , Fxii deficiency , Thrombotic events .

Maria Luigia Randi: KOL impact

Concepts related to the work of other authors for which for which Maria Luigia Randi has influence: Essential thrombocythemia , Polycythemia vera , Myeloproliferative neoplasms , Janus kinase , Primary myelofibrosis , Platelet count , Patients pv .

KOL Resume for Maria Luigia Randi

Year
2021

First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy

2020

First Clinical Medicine, Department of Internal Medicine-DIMED, University of Padua, via Giustiniani 2, 35123 Padova, Italy.

Department of Medicine (DIMED), University of Padova, Padua, Italy;

2019

University of Padua Medical School, Department of Medicine, Padua, Italy.

2018

First Medical Clinic, Department of Medicine‐DIMED, University of Padova, Padova, Italy

2017

Department of Medicine, DIMED‐ University of Padua, Padua, Italy

2016

Internal Medicine Dept., DIMED, University Hospital, Padova, Italy

2015

Division of Hematology University of Padua Padua Italy

2014

University of Padua Department of Medicine ‐DIMED Padua Italy

2013

University of Padua Medical School Department of Medicine‐DIMED Padua Italy

2012

Department of Internal Medicine, University of Padua, Padua Italy

2011

From the Ospedali Riuniti di Bergamo, Bergamo

University of Florence, Florence, Italy

and Mayo Clinic, Rochester, MN.

S. Bortolo Hospital, Vicenza

2010

Department of Medical and Surgical Sciences, Internal Medicine, University of Padua Medical School, Padua, Italy

2009

Department of Medical and Surgical Sciences, University of Padua Medical School, Italy

2008

Department of Medical and Surgical Sciences and

University Unit, Padova, Italy

2007

Dipartimento di Scienze Medico-Chirurgiche, Sezione Medicina Interna, Università di Padova, Padova;

2006

Internal Medicine, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy

2005

Internal Medicine, Department of Medical and Surgical Sciences, University of Padua Medical School, Padua,

2004

From the Consorzio Mario Negri Sud, Santa Maria Imbaro; Policlinico S Orsola, Bologna; Ospedale S Gerardo, Monza; University of Padua, Dip. Scienze Mediche e Chirurgiche, Padova; Ospedale Umberto I, Venezia-Mestre; Catholic University School of Medicine, Rome; Ospedali Riuniti, Bergamo; Ospedale di Reggio Emilia; Ospedale S Giovanni e Paolo, Venezia; University of Rome “La Sapienza,” Italy; Sahlgrenska Hospital, Göteborg, Sweden; Department of Hematology and Blood Coagulation, University of Vienna, Austria; Tel-Aviv Souraski Medical Center, Israel; and Hospital Universitario S Carlos, Madrid, Spain

Reprints: Fabrizio Fabris, Department of Medical and Surgical Sciences, via Ospedale 105, 35128 Padova, Italy; e-mail: fabrizio.fabris{at}unipd.it.

University of Padua Medical School, Department of Medical and Surgical Sciences, Padua, Italy

2003

Department of Medical and Surgical Sciences, II Chair of Internal Medicine, University of Padua Medical School, via Ospedale 105, 35128, Padua, Italy

2002

From the Clinica Medica II, Department of Medical and Surgical Sciences, University of Padua Medical School, Padova, Italy

2001

Department of Medical and Surgical Sciences, University of Padua Medical School and

2000

Department of Medical and Surgical Science, II Chair of Internal Medicine

Transfusion Center, Padua City Hospital, Padua, Italy

1999

From the Department of Medical and Surgical Sciences, II Chair of Internal Medicine; and

Institute of Medical Semeiotics, Chair of Internal Medicine

1998

From the Institute of Medical Semeiotics, II Chair of Internal Medicine, University of Padua Medical School, Padua, Italy

1997

Institute of Medical Semiotics, Second Chair of Internal Medicine and of Clinical Methodology, University of Padua Medical School, Padua, Italy

1996

Institute of Medical Semeiotics, Chairs of Semeiotic and Internal Medicine, University of Padua Medical School, Padua, Italy

1995

Institute of Medical Semeiotic, Fourth Chair of Internal Medicine, University of Padua Medical School, Padua, Italy

1994

Institute of Medical Semeiotics, Padua Medical School, Italy.

1993

Institute of Medical Semeiotics, Padua University School of Medicine, Padova, Italy.

1992

Universita'degli Studi di Padova, Istituto di Semeiotica Medica, 35100 Padova, Italy

1991

Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua, Italy

1990

University of Padua Medical School, Institute of Medical Semeiotics, Second Chair of Medicine, Padua, Italy.

1989

University of Padua Medical School, Institute of Medical Semeiotics and Second Chair of Medicine, Padova, Italy

1988

Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Italy.

1987

Padua

1985

University of Padua Medical School, Institute of Medical Semeiotics, Second Chair of Medicine and Blood Bank Transfusion Center, Padua, Italy

1984

Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua;, Central Laboratory, Padua City Hospital, Padua, Italy

1983

Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy

Istituto di Semeiotica Medica, Università degli Studi di Padova, Via Ospedale Civile 105, 35100, Padova, Italia

Prominent publications by Maria Luigia Randi

KOL-Index: 10996 . PURPOSE: The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study examined the clinical relevance of such a distinction. METHODS: Representatives from seven international centers of excellence for myeloproliferative neoplasms convened to create a ...
Known for Essential Thrombocythemia | Early Prefibrotic Pmf | 15 Years | International Study
KOL-Index: 9667 . Essential thrombocythemia (ET) may occur in women of childbearing age. To investigate the risk of pregnancy complications, we studied 103 pregnancies that occurred in 62 women with ET. The 2-tailed Fisher exact test showed that pregnancy outcome was independent from that of a previous pregnancy. The rate of live birth was 64%, and 51% of pregnancies were uneventful. Maternal complications ...
Known for Pregnancy Complications | Fetal Loss | Platelet Count | Patients Essential Thrombocythemia
KOL-Index: 8954 . By means of immunoblotting and monoclonal antibody immobilization of platelet antigens (MAIPA) we have studied the specificity of antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia defined as presence of anticardiolipin IgG and a platelet count below 100 x 10(9)/l. The study group consisted of 10 patients with systemic lupus erythematosus (SLE), 8 ...
Known for Patients Antiphospholipid Antibodies | Platelet Antigens | Chronic Itp | Antiphospholipid Syndrome
KOL-Index: 8900 . Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories based on the respective absence or presence of either age > 60 years or history of thrombosis. In an international study of 891 patients with ...
Known for Health Organization | Essential Thrombocythemia | International Prognostic | Thrombosis Risk
KOL-Index: 8531 . JAK2 617V>F mutation occurs in a homozygous state in 25% to 30% of patients with polycythemia vera (PV) and 2% to 4% with essential thrombocythemia (ET). Whether homozygosity associates with distinct clinical phenotypes is still under debate. This retrospective multicenter study considered 118 JAK2 617V>F homozygous patients (104 PV, 14 ET) whose clinical characteristics were compared with ...
Known for Homozygous Jak2 | Essential Thrombocythemia | Polycythemia Vera | Leukocyte Count
KOL-Index: 8137 . To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with myeloproliferative neoplasms (MPN) we compared 48 patients with MPN and CVT (group MPN-CVT) to 87 with MPN and other venous thrombosis (group MPN-VT) and 178 with MPN and no thrombosis (group MPN-NoT) matched by sex, age at diagnosis of MPN (±5 years) and type of MPN. The study ...
Known for Myeloproliferative Neoplasms | Cerebral Vein Thrombosis | Cvt Patients | Essential Thrombocythemia
KOL-Index: 7895 . In an international collaborative study, a central histologic review identified 891 patients with essential thrombocythemia, strictly defined by World Health Organization criteria. After a median follow-up of 6.2 years, 109 (12%) patients experienced arterial (n = 79) or venous (n = 37) thrombosis. In multivariable analysis, predictors of arterial thrombosis included age more than 60 years ...
Known for Venous Thrombosis | International Study | 891 Patients | Janus Kinase
KOL-Index: 7718 . Polycythemia vera (PV) is currently diagnosed by the World Health Organization (WHO) criteria regarding hemoglobin (HB) levels and JAK2V617F and related mutations or by the British Committee for Standards in Haematology (BCSH) guidelines predominantly based on hematocrit (HCT) values (>52% in men and >48% in women) in JAK2 mutated patients. We examined clinical features at diagnosis and ...
Known for Polycythemia Vera | Mpv Patients | Bone Marrow | Overt Pv
KOL-Index: 7556 . Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequent in women and arterial thrombosis and abnormal karyotype in men. Considering patients ...
Known for International Study | Abnormal Karyotype | 1545 Patients | Leukemic Transformation
KOL-Index: 7125 . The presence and specificity of antiplatelet autoantibodies in 32 patients with primary and 18 patients with secondary autoimmune thrombocytopenic purpura (AITP), as well as 11 nonthrombocytopenic patients with systemic autoimmune diseases, were studied. By means of the direct and indirect monoclonal antibody immobilization of platelet antigen (MAIPA) assay, antiplatelet autoantibodies ...
Known for Autoimmune Diseases | Patients Thrombocytopenia | Gps Iib Iiia | Platelet Glycoproteins
KOL-Index: 6993 . We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of polycythemia vera (PV), but a hemoglobin level of <18.5 g/dL in males (range 16.0-18.4) and <16.5 g/dL in females (range 15.0-16.4). This cohort operationally referred to as masked PV (mPV) was compared with 257 patients ...
Known for Polycythemia Vera | Janus Kinase | Pv Mpv | Acute Leukemia
KOL-Index: 6990 . BACKGROUND: As reported by major clinical series in the literature, about 2% of patients receiving unfractionated heparin (UFH) develop immune-mediated (type II) heparin-induced thrombocytopenia (HIT) that may be complicated in 30-75% of cases by a paradoxical thrombotic syndrome (HITTS), either arterial or venous. HITTS carries relevant rates of mortality and morbidity, amongst which ...
Known for Arterial Thrombosis | Hit Patients | Antibodies Anticoagulants | Immune Mediated

Key People For Essential Thrombocythemia

Top KOLs in the world
#1
Tefferi Tefferi
essential thrombocythemia primary myelofibrosis polycythemia vera
#2
Tiziano Barbui
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#3
Guido Finazzi
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#4
Alessandro Maria Vannucchi
speakers bureau board directors polycythemia vera
#5
Claire N Harrison
speakers bureau board directors advisory committees
#6
Francesco Passamonti
speakers bureau polycythemia vera board directors

First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy | Department of Medicine-DIMED, University of Padua, Via Giustiniani 2, 35128, Padua, Italy | First Medical Clinic, Department of Medicine—DIMED, University of Padua,